Emphysema clinical trials

The registry lists 382 studies for Emphysema across more than 10 countries. 59 are recruiting or about to start. 122 of them are mainly about Emphysema (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05. Counting its narrower condition alpha 1-Antitrypsin Deficiency too: 495 studies, 83 open.

Get an email when these change. Save the Emphysema studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 226
Recruiting: 50
Status unknown: 37
Terminated: 28
Withdrawn: 16
Active, not recruiting: 14

Phase

Phase 2: 70
Phase 3: 40
Phase 4: 36
Phase 1: 27
Early Phase 1: 3

Where

United States: 162
Germany: 54
United Kingdom: 46
Netherlands: 40
Canada: 31
France: 27

Who runs them

Aeris Therapeutics (17) · AstraZeneca (16) · University Medical Center Groningen (11) · University of Zurich (10) · Boston Scientific Corporation (9) · GlaxoSmithKline (9) · National Heart, Lung, and Blood Institute (NHLBI) (9) · Pulmonx Corporation (9)

What is being tested here

Drugs under test in Emphysema studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Alpha 1-Antitrypsin	1	0	3
Quercetin	1	0	2
Brenipatide	1	0	1
Rituximab	1	0	1
Alemtuzumab	1	0	1
Fludarabine	1	0	1
Thiotepa	1	0	1
Granulocyte Colony-Stimulating Factor	1	0	1
Hydroxyurea	1	0	1
Aclidinium	0	9	12

Drug classes tested here Antimuscarinics 21 · Corticosteroids 10 · Bronchodilators 7

Coming up

1phase 3 study under way

21studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Sep 2027A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) · Phase 3 · Grifols Therapeutics LLC
Nov 2026The Effect of Treatment of Emphysema With Endobronchial Valves on the Diaphragm Mobility · Aarhus University Hospital
Dec 2026STRIVE Post-Market Registry Study · Olympus Corporation of the Americas
Dec 2026Analysing Peripheral Skeletal Muscle Function Before and After Endobronchial Valve Treatment · University Medical Center Groningen
Dec 2026Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction · Beth Israel Deaconess Medical Center
Dec 2026Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath · ChromX Health
Dec 2026Zephyr Valve Registry (ZEVR) · Pulmonx Corporation
Dec 2026A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema · Shanghai Chest Hospital
Jan 2027Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA · Columbia University
Jan 2027Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap · Gelb, Arthur F., M.D.

Who these studies take

Of the 50 Emphysema studies recruiting now, 27 (54%) set no upper age limit and 9 (18%) stop at 75 or younger. 6 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 9 (18%) take healthy volunteers.

Recruiting studies that take each age, of 50
Age	Women	Men
10	6 (12%)	6 (12%)
18	26 (52%)	26 (52%)
30	31 (62%)	31 (62%)
40	47 (94%)	47 (94%)
50	49 (98%)	49 (98%)
65	49 (98%)	49 (98%)
75	46 (92%)	46 (92%)
85	32 (64%)	32 (64%)

Across all 382 studies, recruiting or not: 22% stop at 75 or younger and 3% at 65; 11% take children; 0% are for women only and 3% for men only; 13% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Emphysema studies take

Of 19 phase 2 interventional studies under Emphysema, half reached primary completion within 31 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	31 mo16–50 · 19 studies	—	—
Phase 4	14 mo14–30 · 13 studies	—	—
Interventional, no phase	37 mo22–56 · 60 studies	—	44 mo28–58 · 40 studies
Observational	66 mo35–… · 45 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 382. Browse all 382 → or search them.